25th Nov 2019 13:47
(Alliance News) - US regulators have granted a cancer treatment developed by Hutchison China MediTech Ltd orphan drug designation, Hutchison said Monday.
Surufatinib is being developed as a treatment for pancreatic neuroendocrine tumours. Orphan drug designation is given to treatments for disease which affect few people, making their commercial development not normally financially viable.
Hong Kong-based Hutchison is looking at surufatinib in multiple solid tumours in both the US and China, as both a standalone treatment and with other drugs.
Hutchison Chief Executive Christian Hogg said: "NET is an area of significant unmet medical need. The current treatment options are very limited.
"The US Food & Drug Administration granting orphan designation is a positive step and continues to reinforce the importance of our research and development in bringing surufatinib to more patients in need."
Hutchison shares were 3.5% lower on Monday afternoon in London at 362.08 pence each.
By George Collard; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed